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To the Editor,
The detection of anti-SARS-CoV-2 antibodies is valuable to
improve the sensitivity of pathogenic diagnosis for COVID-
19, to identify convalescent plasma donors, to screen the
population to determine the seroprevalence and to assess
the persistence of protection in the population or at the
individual level [1–3]. A wide range of serology immuno-
assays have been developed to complement the RT-PCR,
with different SARS-CoV-2 antigen targets and formats [4].
Due to thewidespread dissemination of thesemethods and
the limited experience with these new assays, it is crucial
for laboratories to rigorously validate thesemethods before
broad introduction into routine clinical practice [1, 3, 5].
Recently, the performances of the Elecsys assay have
been published. The Elecsys anti-SARS-CoV-2 is an elec-
trochemiluminescent immunoassay (ECLIA) for the in vitro
qualitative detection of total antibodies, including IgG, to
SARS-CoV-2 in human serum and plasma. The assay uses a
recombinant protein representing the nucleocapsid anti-
gen for the determination of antibodies against SARS-CoV-
2. In our study, all measurements were performed on the
cobas® e801 (Roche Diagnostics®). Three independent
studies found a specificity ranging from98.7 to 100% [6–8].
Sensitivities two weeks post-symptoms were 89.4% (n=47)
[7], 91.1% (n=79) [6], and 100% (n=18) [8], using the man-
ufacturer’s cut-off (i.e., COI ≥ 1.0). In one of these studies,
optimization of the cut-off, as determined by ROC curve
analyses, was associated with a sensitivity of 95.1%
without diminishing the specificity of 100%, suggesting
that cut-off optimization may increase the detection rate in
the population [6]. Antibody kinetics is amatter of concern,
especially because emerging data showed that the persis-
tence of antibodies may last only 2 to 3 months, offering a
strong note of caution against the idea of “immunity cer-
tificate” [9]. In this study, 40 and 13 percent of asymp-
tomatic and symptomatic patients had antibody levels
falling below the threshold for positivity in the early
convalescent phase, i.e., eight weeks after discharge from
the hospital. However, even low levels of neutralizing an-
tibodies may still be protective, arguing for the use of
optimized cut-off to detect those with low antibody levels.
The aim of the present study was to assess the longitudinal
kinetics of anti-SARS-CoV-2 antibodies since symptom
onset, in a large cohort of patients, and by using the
manufacturer’s cut-off and the optimized cut-off (i.e.,
COI > 0.165) recently published [6].
This study has been conducted from March 21 to May
25, 2020 at the clinical biology laboratory of the Clinique
Saint-Luc Bouge (SLBO, Namur, Belgium). A total of 150
serum samples were obtained from 94 patients confirmed
positive to SARS-CoV-2 by RT-PCR. Information on the days
since the onset of symptoms was collected from the med-
ical records. The RT-PCR for SARS-CoV-2 determination in
respiratory samples (nasopharyngeal swab samples) was
performed on a LightCycler® 480 Instrument II (Roche
Diagnostics®) using the LightMix® Modular SARS-CoV
E-gene set. Blood samples collected from patients into
serum-gel tubes (BD Vacutainer® 8.5 mL tubes, Becton
Dickinson, New Jersey, USA) or lithium-heparin plasma
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tubes (BD Vacutainer® 4.0 mL tubes) according to stan-
dardized operating procedure and manufacturer recom-
mendations. Sampleswere centrifuged for 10min at 1,885×g
(ACU Modular® Pre Analytics, Roche Diagnostics®). Sera
and plasma sampleswere stored at −20 °C and thawed 1 h at
room temperature on the day of the analysis. Re-thawed
samples were vortexed before the analysis. Antibody ki-
netics was evaluated using COI results obtained in all
samples using the following time frames (d, days): 0–5 d, 6–
8 d, 9–11 d, 12–14 d, 15–17 d, 18–20 d, 21–23 d, 24–30 d, 31–
40 d, 41–63 d.Maximumone serumper category per patient
was allowed leading to the exclusion of five samples
(number of samples included = 145). The mean COI results
(and standard errors) were plotted against the different time
frames. Smoothing splines with four knots were used to
estimate the time kinetics curve. Data analysis was per-
formed using GraphPad Prism® software (version 8.2.1, San
Diego, CA, USA). Our study fulfilled the Ethical principles
provided by the Declaration of Helsinki.
Figure 1A shows the frequency of reported symptoms.
Fever was themost frequent symptom (68.1%), followed by
cough (60.4%), fatigue (58.2%), difficulty breathing
(45.1%), and muscle aches (31.9%). Less frequency re-
ported symptoms were chest pain (6.6%), sore throat
(6.6%), and loss of smell (6.6%). The median number of
symptomsper patientwas 3 (Figure 1B). Figure 2 reports the
antibody kinetics at different days from symptom onset in
145 sera samples from 94 patient and shows the number
and percentage of positive test results for each time cate-
gory, according to the manufacturer’s cut-off and the
optimized cut-off (>0.165) [6], respectively. Positivity rates
prior day 15 were insufficient to recommend the use of this
serological assay in clinical practice in this timeframe
whatever the cut-off used. The manufacturer’s cut-off
provided a positivity rate from 0 to 84.6% and the opti-
mized cut-off, from 16.7 to 100%. After 15 days since
symptom onset, positivity rates increased from 86.7 to
100% using the manufacturer’s cut-off and from 89.5 to
100% using the optimized cut-off (Figure 2).
Current data suggest that seroconversion occurs
approximately 7–14 days after symptom onset [1]. In our
study, a gradual increase of total antibodies since the onset
of COVID-19 symptoms was observed (Figure 2). After
±7 days, the positivity rates in our cohort was around 70%
meaning that one could wait few days to improve detection
of SARS-CoV-2 antibodies in a broader population. From
day 15, and based on the manufacturer’s cut-off
(i.e., COI ≥ 1.0), eight serum samples were considered
negative giving a mean positivity rate of 90.8%. Using the
optimized cut-off (i.e., >0.165) [6], the mean positivity rate
reaches 97.7%. From day 24, the positivity rate increased to
100% (Figure 2).
Other studies confirmed that early anti-SARS-CoV-2
antibody determination had limited positivity rates. In a
study on 37 COVID-19 patients, Padoan et al. observed that
12 days since fever onset were required to reach 100%
sensitivity for IgG on the Maglumi 2000 Plus CLIA
(chemiluminescent assay) [10]. A lower sensitivity (88%)
was however found for IgM and a cut-off refinement was
therefore suggested [10]. Tang et al. compared the Abbott
IgG, the Euroimmun IgG, and the Elecsys total antibodies
SARS-CoV-2 assays in 48 COVID-19 patients [7, 11]. After
twoweeks since symptom onset, they found sensitivities of
93.8, 85.4, and 89.4%, respectively. The sensitivity before
day 14 was higher for the Elecsys assay compare to Abbott
and Euroimmun assays [11]. Nevertheless, none of the three
assays had sufficient sensitivity to be useful in identifying
post-COVID-19 infection before day 14. Montesinos et al.
showed equivalent performance of five anti-SARS-CoV-2
assays (Euroimmun Anti-SARS-CoV-2 ELISA IgG, and IgA
assays, Maglumi™2019-n-Cov IgG and IgM CLIA assay and
Figure 1: Frequency and number of symptoms in the studied COVID-
19 patients. (A) frequency of reported symptoms, (B) number of
symptoms per patient.
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three lateral flow assays) 14 days after the symptoms onset
[12]. Overall, sensitivities 15 days after the onset of COVID-
19 symptoms varied from 87.5 to 93.93% (n=32–33,
depending on the assay considered) and were higher
compared to early determinations. Pan et al. found
increasing positivity rates of 3.6, 57.1, and 96.8% in early
(0–7 days, n=27), intermediate (8–14 days, n=28) and late
stage (>15 days, n=31) since symptom onset on a colloidal
gold-based immunochromatographic strip assay (Zhuhai
Livzon Diagnostic Inc.) in 67 COVID-19 confirmed patients
[13]. From 17 days since symptom onset, Long et al. found
100% positivity for IgG (MCLIA kits, Bioscience Co.) in 285
patients with COVID-19 [14]. IgG positivity rates at 11–
13 days and 14–16 days since symptom onset were lower
with respective rates of 68.6 and 90%, respectively.
In conclusion, we found a continuous antibody increase
since symptom onset. We confirmed that a minimum of 2
weeks since symptom onset is needed to increase anti-
SARS-CoV-2 detection. The use of an optimized cut-off
allowed to increase positivity rates and provides earlier de-
tections. Further studies designed to evaluate long-term
antibodykineticsarealsoneededtoaddressthepersistenceof
the immunity response and the performances of the different
assays in detecting potential lower levels of antibodies.
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